[Adverse reactions due to monoclonal antibodies in the treatment of allergic diseases. Group Positioning: Comité de Alergia a Medicamentos del Colegio Mexicano de Inmunología Clínica y Alergia (CMICA 2024-2025)].

Background: Monoclonal antibodies are a therapeutic option for allergy, autoimmune, oncological diseases, among others, and work by inhibiting interactions between effector molecules and their specific receptors. However, the increasing use of these drugs has led to an increase in adverse drug reactions (ADRs). ADRs are defined as unexpected responses to therapeutic treatments. They are divided into type A, derived from the pharmacokinetics of the treatment or as a host immune response type B.

Objectives: Review of the use of monoclonal antibodies in the treatment of allergic diseases, addressing key aspects such as pharmacokinetics, pharmacodynamics, posology, contraindications and adverse reactions.

Methodology: A search of major medical databases on monoclonal antibodies for the treatment of allergic diseases was conducted. It was limited to original articles in English and Spanish, published between 2014 and 2024.

Results: Monoclonal antibodies for allergic diseases are described, including their mechanism of action, trade name, indications, posology, contraindications and adverse reactions.

Conclusion: The collection of data on biological drugs is crucial for a comprehensive and up-to-date understanding of their clinical use. Understanding adverse reactions improves diagnosis and the quality of medical care.